Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Kura Oncology Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
KURA
Nasdaq
8731
https://www.kuraoncology.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Kura Oncology Inc
Kura Oncology to Participate in Stifel Targeted Oncology Forum
- Apr 10th, 2024 11:30 am
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Apr 5th, 2024 11:30 am
Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma
- Mar 6th, 2024 12:30 pm
Kura Oncology, Inc. (NASDAQ:KURA) Q4 2023 Earnings Call Transcript
- Feb 28th, 2024 2:56 pm
Q4 2023 Kura Oncology Inc Earnings Call
- Feb 28th, 2024 11:56 am
Kura Oncology Inc (KURA) Reports Q4 and Full Year 2023 Financial Results
- Feb 27th, 2024 9:44 pm
Kura Oncology Reports Fourth Quarter and Full Year 2023 Financial Results
- Feb 27th, 2024 9:01 pm
Kura Oncology Doses First Patient in KOMET-008 Trial of Ziftomenib in Combination with Standards of Care, Including FLT3 Inhibitor, in Acute Myeloid Leukemia
- Feb 26th, 2024 12:30 pm
Kura Oncology to Participate in Three Upcoming Investor Conferences
- Feb 22nd, 2024 12:30 pm
Kura Oncology to Report Fourth Quarter and Full Year 2023 Financial Results
- Feb 20th, 2024 12:30 pm
Chief Medical Officer Stephen Dale Sells Shares of Kura Oncology Inc
- Feb 1st, 2024 8:01 pm
Kura Makes Good On Its $150 Million Infusion And Shoots Up 12%
- Jan 30th, 2024 9:07 pm
Kura Oncology Reports Positive Preliminary Ziftomenib Combination Data in Acute Myeloid Leukemia
- Jan 30th, 2024 12:00 pm
Is There An Opportunity With Kura Oncology, Inc.'s (NASDAQ:KURA) 42% Undervaluation?
- Jan 25th, 2024 12:06 pm
Kura Oncology Rockets 46% Before Unveiling Cancer Drug Test Results — Here's Why
- Jan 24th, 2024 9:22 pm
Why Is Cancer Focused Kura Oncology Stock Is Trading Higher Today?
- Jan 24th, 2024 6:16 pm
Kura Oncology Announces Oversubscribed $150 Million Private Placement
- Jan 24th, 2024 12:00 pm
Kura Oncology’s Menin Inhibitor Ziftomenib Selected for The Leukemia & Lymphoma Society’s Pediatric Acute Leukemia (PedAL) Master Clinical Trial
- Dec 8th, 2023 12:30 pm
Kura Oncology to Participate in the JMP Securities Hematology and Oncology Summit
- Nov 28th, 2023 12:30 pm
Kura Oncology, Inc. (NASDAQ:KURA) Q3 2023 Earnings Call Transcript
- Nov 5th, 2023 8:44 pm
Scroll